Evotec AG today announced having signed a transaction agreement with Sanofi to integrate Sanofi’s infectious disease unit into its organisation. Pursuant to this agreement, Evotec will also licence-in the majority of Sanofi’s infectious disease research portfolio and initiatives. This successfully seals the exclusive negotiations between the two companies and completion of the required legal social process, initiated on 08 March 2018. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-sanofi-sign-definitive-agreement-to-combat-infectious-diseases-5695
Evotec forms academic BRIDGE LAB591 with Arix Bioscience and Fred Hutchinson Cancer Research Center
Evotec AG announced today the formation of the LAB591 academic BRIDGE with Arix Bioscience plc (“Arix”, London Stock Exchange: ARIX ) and the Fred Hutchinson Cancer Research Center (“Fred Hutch”). LAB591 aims to accelerate research discoveries at Fred Hutch and leverage these discoveries to form new companies focused on cancer and infectious disease drug development. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-forms-academic-bridge-lab591-with-arix-bioscience-and-fred-hutchinson-cancer-research-center-5693
Evotec expands iPSC platform with licence from ID Pharma
Evotec AG today announced that it has expanded its iPSC platform through a licence agreement with ID Pharma. The non-exclusive licence enables Evotec to both work with and differentiate induced pluripotent stem cells (“iPSC”) produced with ID Pharma’s Sendai virus (“SeV”) vector technology. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-ipsc-platform-with-licence-from-id-pharma-5689
Evotec and Celgene enter into strategic oncology partnership
Evotec AG announced today that Evotec and Celgene Corporation have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-celgene-enter-into-strategic-oncology-partnership-5687
Evotec reports first quarter 2018 results and provides corporate update
Evotec AG today reported financial results and provided corporate updates for the first quarter of 2018. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-reports-first-quarter-2018-results-and-provides-corporate-update-5682
Evotec and Carna Biosciences collaborate on INDiGO platform
Evotec AG today announced a strategic collaboration with Carna Biosciences, Incorporated (“Carna”). Carna will access Evotec’s INDiGO platform to accelerate the development of its programme CB-1763, which is being developed for the treatment of blood cancer, through to the submission of an Investigational New Drug Application (“IND”) with the U.S. Food and Drug Administration. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-and-carna-biosciences-collaborate-on-indigo-platform-5680
Evotec to present at upcoming investor conferences
Evotec AG announced today that its management will be presenting at the Deutsche Bank 43rd Annual Health Care Conference in Boston, USA, at the Bank of America Merrill Lynch 2018 Healthcare Conference in Las Vegas, USA, at the Berenberg USA Conference 2018 in Tarrytown, USA, at the Jefferies 2018 Global Healthcare Conference in New York, USA, and at the dbAccess Berlin Conference in Berlin, Germany. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-to-present-at-upcoming-investor-conferences-5678
Evotec expands CRISPR-based technology offering with licence from ERS Genomics
Evotec AG today announced that it has expanded its CRISPR service offering with the addition of a licence from ERS Genomics Limited. With this licence, Evotec gains access to the leading technology for gene editing, thereby complementing and expanding its existing service offering in the CRISPR gene editing space. The new licence from ERS Genomics Limited complements and expands Evotec’s existing CRISPR licences through the Broad Institute with gene editing technology from Emmanuelle Charpentier and others. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-expands-crispr-based-technology-offering-with-licence-from-ers-genomics-5674
Evotec AG to report first quarter 2018 results on 09 May 2018
Evotec AG will report its financial results for the first quarter of 2018 on Wednesday, 09 May 2018. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Furthermore, the Management Board will present an outlook for the fiscal year 2018. The conference call will be held in English. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/evotec-ag-to-report-first-quarter-2018-results-on-09-may-2018-5676
Excelling Together for the Benefit of Women Suffering from Endometriosis
Five years after initiating our endometriosis alliance with Bayer, we draw some very important lessons from one of our key performance-based alliances – and share our insights. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/excelling-together-for-the-benefit-of-women-suffering-from-endometriosis-5671